文献速递冠心病心律失常

房颤患者PCI术后双联与三联抗栓治疗的安全性和有效性:基于NOAC随机临床试验的系统综述与荟萃分析

Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
PubMed 文献 · Eur Heart J · 2019-01-01

结果显示DAT显著降低出血风险(RR 0.66,95%CI 0.56-0.78;P<0.0001),但增加支架内血栓风险(RR 1.59,95%CI 1.01-2.50;P=0.04),心肌梗死风险有升高趋势;全因死亡、心血管死亡、卒中和主要不良心血管事件无显著差异。

要点

  • DAT较TAT显著降低ISTH大出血或临床相关非大出血风险(RR 0.66)。
  • DAT增加支架内血栓风险(RR 1.59),心肌梗死风险有升高趋势。
  • NOAC-based DAT较VKA-TAT显著降低颅内出血风险(RR 0.33)。

核心结论

  • 双联抗栓治疗(尤其NOAC联合P2Y12抑制剂)可减少出血包括大出血和颅内出血,但被心脏缺血事件(主要为支架相关)风险增加所抵消,脑血管缺血事件未增加。

主要发现

  • 主要安全终点(ISTH大出血或临床相关非大出血)DAT显著低于TAT(RR 0.66,95%CI 0.56-0.78;P<0.0001;I2=69%),所有出血定义一致。
  • 支架内血栓DAT显著高于TAT(RR 1.59,95%CI 1.01-2.50;P=0.04;I2=0%)。
  • 心肌梗死风险DAT有升高趋势。
  • 全因死亡、心血管死亡、卒中和主要不良心血管事件无显著差异。
  • NOAC-based DAT vs VKA-TAT结果一致,且颅内出血显著减少(RR 0.33,95%CI 0.17-0.65;P=0.001;I2=0%)。

关键数值与推荐

  • 主要安全终点为ISTH大出血或临床相关非大出血。
  • DAT相比TAT的出血风险RR 0.66(95%CI 0.56-0.78;P<0.0001)。
  • DAT相比TAT的支架内血栓风险RR 1.59(95%CI 1.01-2.50;P=0.04)。
  • NOAC-based DAT相比VKA-TAT的颅内出血风险RR 0.33(95%CI 0.17-0.65;P=0.001)。

临床怎么用

  • 对于房颤合并ACS或接受PCI的患者,优先考虑NOAC联合P2Y12抑制剂的双联抗栓治疗以降低出血风险。
  • 需权衡DAT带来的支架内血栓和心肌梗死风险升高,个体化评估缺血与出血风险。

局限性

  • 出血终点异质性较高(I2=69%)。
  • 纳入试验数量有限(4项),结论需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TAT) in patients with atrial fibrillation (AF) and acute coronary syndrome or who underwent percutaneous coronary intervention (PCI). METHODS AND RESULTS: A systematic review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials comparing DAT vs. TAT in AF patients undergoing PCI. Four trials encompassing 10 234 patients (DAT = 5496 vs. TAT = 4738) were included. The primary safety endpoint (ISTH major or clinically relevant non-major bleeding) was significantly lower with DAT compared with TAT [risk ratio (RR) 0.66, 95% confidence interval (CI) 0.56-0.78; P < 0.0001; I2 = 69%], which was consistent across all available bleeding definitions. This benefit was counterbalanced by a significant increase of stent thrombosis (RR 1.59, 95% CI 1.01-2.50; P = 0.04; I2 = 0%) and a trend towards higher risk of myocardial infarction with DAT. There were no significant differences in all-cause and cardiovascular death, stroke and major adverse cardiovascular events. The comparison of NOAC-based DAT vs. vitamin K antagonist (VKA)-TAT yielded consistent results and a significant reduction of intracranial haemorrhage (RR 0.33, 95% CI 0.17-0.65; P = 0.001; I2 = 0%). CONCLUSION: Double antithrombotic therapy, particularly if consisting of a NOAC instead of VKA and a P2Y12 inhibitor, is associated with a reduction of bleeding, including major and intracranial haemorrhages. This benefit is however counterbalanced by a higher risk of cardiac-mainly stent-related-but not cerebrovascular ischaemic occurrences.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019. PMID: 31651946. doi:10.1093/eurheartj/ehz732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。